Oh, yes. Thank you very much. So in our study, we evaluated the whole brain irradiation with hippocampal sparing and dose escalation on metastases. And the endpoint of the study was neurocognitive testing and biological imaging in patients with multiple brain metastases, 4 to 10. This is a phase 2 prospective randomized multicenter trial, the Hipporad trial. And the background are first the data from NRG Oncology CC01 trials published five years ago, in which was demonstrated that whole brain radiation therapy plus memantine was better concerning preservation of cognitive function in comparison to whole brain radiation alone...
Oh, yes. Thank you very much. So in our study, we evaluated the whole brain irradiation with hippocampal sparing and dose escalation on metastases. And the endpoint of the study was neurocognitive testing and biological imaging in patients with multiple brain metastases, 4 to 10. This is a phase 2 prospective randomized multicenter trial, the Hipporad trial. And the background are first the data from NRG Oncology CC01 trials published five years ago, in which was demonstrated that whole brain radiation therapy plus memantine was better concerning preservation of cognitive function in comparison to whole brain radiation alone. And this was a randomized phase three trial. However, we have old data showing that actually local tumor control correlates or could correlate with neurocognitive function and also is a delivered dose. So what we did in this study, and this is special, and this is a difference to the North American trial, that we escalated the dose on each lesion similar to a radiosurgery. So we increased the dose on each lesion with a goal to increase also the local tumor control. So if I can say like, so this is actually a citation from the old study that uncontrolled tumor is bad for the brain. So this is also a fact. So summarizing, we tried to improve the treatment and the technology of the whole brain radiation therapy, the treatment planning. And before we started with this study, we performed a planning trial. And in this trial, we evaluated different modalities for the dose escalation and hippocampus avoidance included in the same treatment plan. We published the data in the Journal and we concluded that a simultaneous integrated boost technique is better than whole brain irradiation plus radiosurgery boost. So at the end, we developed this strategy. We also developed the hippocampal blocking techniques to spare better the hippocampus. And we also performed a multi-center, multi-platform pattern of practice analysis of single-isocenter, multi-target stereotactic radiosurgery. And with this background, we performed the HIPPORAD trial. Yes. Thank you.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
